Jason Keyes
Net worth: 289 513 $ as of 30/07/2026
Net worth: 289 513 $ as of 30/07/2026
Mr. Jason A. Keyes is a Chief Financial Officer & Executive Vice President at Blossomhill Therapeutics, Inc. and an Independent Director at Actuate Therapeutics, Inc. He is on the Board of Directors at Actuate Therapeutics, Inc. Mr. Keyes was previously employed as an Independent Director by Sesen Bio, Inc., a Chief Financial Officer by Equillium, Inc., a Chief Financial Officer & Executive Vice President by Orexigen Therapeutics, Inc., a Senior Director-Finance by Amylin Pharmaceuticals, Inc., and a Head-Finance & Strategy by Amgen, Inc. He received his undergraduate degree from Stanford University, a graduate degree from Stanford University and an MBA from UCLA Anderson School of Management.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
EQUILLIUM, INC. 0.2% | 13/02/2025 | 126,633 ( 0.2% ) | 278 593 $ | 30/07/2026 |
| 09/08/2026 | 700 ( 0% ) | 10 920 $ | 30/07/2026 | |
| 20/05/2026 | 0 ( -.--% ) | - $ | 30/07/2026 |
| Companies | Position | Start |
|---|---|---|
| ACTUATE THERAPEUTICS, INC. | Director/Board Member | 11/08/2024 |
| BLOSSOMHILL THERAPEUTICS, INC. | Director of Finance/CFO | 30/04/2025 |
| Companies | Position | End |
|---|---|---|
| EQUILLIUM, INC. | Director of Finance/CFO | 24/04/2025 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 06/03/2023 |
| OREXIGEN THERAPEUTICS, INC. | Director of Finance/CFO | 22/02/2018 |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Director of Finance/CFO | 31/12/2012 |
| AMGEN INC. | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on the treatment of obesity | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sesen Bio, Inc.
Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
UCLA Anderson School of Management
UCLA Anderson School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops novel therapeutics which target cancers and neurodegenerative diseases | Health Technology |
Equillium, Inc.
Equillium, Inc. BiotechnologyHealth Technology Engages in the development of products for severe immune-inflammatory disorders | Health Technology |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for oncology and autoimmune diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions